COMPASS: A Scandinavian perspective of the projected lifetime cost-effectiveness of rivaroxaban plus aspirin in the COMPASS trial.
Scandinavian Cardiovascular Journal
Lamy A, Ryden L, Tong W, Yuan F, Eikelboom JW; COMPASS Investigators.
September 2026
